Summary
Ambroxol is known to promote bronchial secretion and is used as an expectorant. Previous studies had suggested that high doses of ambroxol could reduce the plasma uric acid concentration. The present study was undertaken to confirm this finding, to determine its dose-response relationship and to identify the underlying mechanism of action.
Using a placebo-controlled, double-blind parallel group design, 48 healthy male volunteers were randomly allocated to receive placebo b.d. and ambroxol 125 mg b.d., 250 mg b.d. or 500 mg b.d. (12 subjects per group). The subjects were hospitalised during a dietary run-in period of 3 days (Days -3 to -1) and a treatment period of 5 days (Days 1 to 5). On Day -1 (baseline) and Days 1 to 5, all urine was collected and blood samples were taken for the analysis of uric acid, creatinine, xanthine and ambroxol. The measurements were repeated four days after treatment had closed.
Steady state plasma concentrations of ambroxol (trough levels) were reached after 2 or 3 days and were linearly related to dose. Ambroxol induced a significant, dose-dependent, reduction in plasma uric acid (250 mg b.d. about 20%; and at 500 mg b.d. about 30%). The diurnally fluctuating uric acid clearance was dose dependently increased and there was no notable effect on creatinine clearance. Plasma hypoxanthine levels were not affected by ambroxol. No severe adverse events were reported and no drug induced changes in the clinical laboratory values were observed.
It is concluded that ambroxol has an uricosuric action following oral administration of higher doses (250 mg-500 mg b.d.) and it is well tolerated.
Similar content being viewed by others
References
Couet W, Girault J, Reigner BG, Ingrand I, Bizonard J, Acerbi D, Chiesi P, Fourtillan JB (1989) Steady state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation. Int J Clin Pharmacol Ther Tox 27: 95–97
Emmerson BT (Ed) (1983) Hyperuricaemia and gout in clinical practice. Sydney: ADIS Health Science Press
Hammer R, Bozler G, Jauch R, Koss FW (1978) Speziesvergleich in Pharmacokinetik and Metabolismus von NA 872 Cl Ambroxol bei Ratte, Kaninchen, Hund und Mensch. Arzneim Forsch/Drug Res 28: 899–903
Janssen TJ, Guelen PJM, Vree TB, Botterblom MHA, Valducci R (1988) Bioavailability of ambroxol sustained release preparations. Part II: Single and multiple oral dose studies in man. Arzneim Forsch/Drug Res 38: 95–97
Jauch R, Bozler G, Hammer R, Koss FW (1978) Ambroxol, Untersuchungen zum Stoffwechsel beim Menschen und zum quantitativen Nachweis in biologischen Proben. Arzneim Forsch/Drug Res 28: 904–911
Kelley WN, Weiner IM (Eds) (1978) Uric acid; Handbook of experimental pharmacology. Vol. 51, Berlin: Springer Verlag
Püschmann S, Engelhorn R, Pharmakologische Untersuchungen des Bromhexin-Metaboliten Ambroxol. Arzneim Forsch/Drug Res (1978) 28: 889–899
Vergin VH, Bishop-Freudling GB, Miczka M, Nitsche V, Strobel K, Matzkies F (1985) Untersuchungen zur Pharmacokinetik und Bioäquivalenz unterschiedlicher Darreichungsformen von Ambroxol. Arzneim Forsch/Drug Res 35: 1591–1595
Wauer RR, Schmalisch G, Menzel K, Schröder M, Müller K, Tiller R, Methfessel G, Sitka U, Koepke E, Plath Ch, Schlegel C, Böttcher M, Köppe I, Fricke U, Severin K, Jacobi R, Schmidt W, Hinkel GK, Nitz I, Kunze D, Reichmann G, Lachmann B, Lampe K, Grauel EL (1982) The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: A controlled double-blind study. Biol Res Pregn 3: 84–91
Wauer RR, Schmalisch G, Hammer H, Buttenberg S, Wiegel H, Huth M (1989) Ambroxol for prevention and treatment of hyaline membrane disease. Eur Respir J 2: 57S-65S
Weiner IM (1979) Urate transport in the nephron. Am J Physiol 237: F85-F92
Wiedey KD (1986) Aspekte zur Mukolyse mit Ambroxol. Therapiewoche 36: 4289–4293
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oosterhuis, B., Storm, G., Cornelissen, P.J.G. et al. Dose-dependent uricosuric effect of ambroxol. Eur J Clin Pharmacol 44, 237–241 (1993). https://doi.org/10.1007/BF00271364
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00271364